Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quest Diagnostics

This article was originally published in The Gray Sheet

Executive Summary

Firm's Nichols Institute develops HIV-I genotyping test intended to identify gene mutation patterns associated with drug resistance and assist in optimal drug therapy selection for individual HIV patients, the firm states in an April 14 release. If a physician suspects drug resistance, the test "can identify mutation patterns in the virus' genes, and point to which drugs are probably not working," states Gregory Critchfield, MD, Quest senior VP and chief medical and science officer. The test is "more robust" and more rapid than competing tests, the company maintains. It "takes advantage of the benefits of full gene sequencing, which enables detection of all gene mutations that occur in a gene," whereas "alternative diagnostic approaches, such as gene chip technology, can miss some gene mutations"
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009941

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel